Introduction {#sec1}
============

Bladder cancer is the 9th most common cancer and ranks 13th in terms of cancer-associated mortality worldwide.[@bib1] In the United Kingdom, bladder cancer accounts for 3% of all new cancer cases, with an estimated 10,171 new cases diagnosed in 2015.[@bib2] Clinically, the lesions will be stratified using the TMN classification, with non--muscle-invasive bladder cancer (NMIBC) classified as stage Tis, Ta, and T1 and muscle-invasive bladder cancer (MIBC) as stage T2, T3, and T4. This distinction is important because the involvement of cancer invading the muscle carries a significantly worse prognosis and requires radical cystectomy, radical chemotherapy, or radical radiotherapy, with or without neoadjuvant chemotherapy. NMIBC has had more favorable survival rates but recurs frequently and has been associated with repeated outpatient visits, cytologic and cystoscopic monitoring, and adjuvant intravesical treatment regimens after transurethral resection.

In the European Union, it has been estimated that the treatment of bladder cancer costs €4.9 billion, representing 5% of the total healthcare cancer costs.[@bib3] In the United States, bladder cancer has been the most costly cancer to treat on a per patient basis.[@bib4]^,^[@bib5] Having estimates of the cost and health-related quality of life (HRQoL) effects of clinical events related to bladder cancer is important as a means of understanding its burden, informing resource allocation decisions, and aiding further research. However, current evidence on such effects has been limited in several ways. First, the distinction between NMIBC recurrence and progression to MIBC has often been overlooked.[@bib5], [@bib6], [@bib7], [@bib8] Second, HRQoL studies have predominantly focused on treatment-specific effects[@bib6], [@bib7], [@bib8], [@bib9] and have not sought to understand the HRQoL effects of specific clinical events such as recurrence and progression. Third, systematic reviews have repeatedly criticized the internal validity of HRQoL analyses, commonly citing the use of retrospective or cross-sectional designs, nonvalidated instruments, short time horizons, and failure to adjust for confounders.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11] Finally, a paucity of UK-specific cost analyses have been reported.

The present study aimed to estimate the expected costs and HRQoL of patients with a diagnosis of NMIBC and evaluate the effects associated with NMIBC recurrence and progression to MIBC. Our study used evidence from a recent randomized controlled trial of patients with intermediate- and high-risk bladder cancer, the BOXIT trial (bladder COX-2 \[cyclo-oxygenase-2\] inhibition trial).

Materials and Methods {#sec2}
=====================

BOXIT Trial {#sec2.1}
-----------

The BOXIT trial (ISRCTN registry no. ISRCTN84681538; Cancer Research UK no. CRUK/07/004) was a randomized phase III placebo-controlled trial that evaluated the addition of celecoxib to standard treatment for patients with NMIBC and an intermediate or a high risk of recurrence. From 2007 to 2012, 472 patients with transitional cell carcinoma NMIBC were recruited. The patients had a mean age of 65.9 years, and most patients were men (79%). The median follow-up at the point of analysis was 44 months (interquartile range, 36-57 months). The trial found no clear treatment benefit for celecoxib, with no significant differences in the interval to the first recurrence of bladder cancer (ie, NMIBC or MIBC) between patients randomized to either celecoxib or placebo for 2 years. Further details of the study design, treatment schedules, patients, and clinical results from the trial have been previously reported.[@bib12]

Clinical Events {#sec2.2}
---------------

At trial entry, cases of intermediate- and high-risk NMIBC were defined according to the clinicopathologic features outlined by the European Association of Urology 2002 guidelines.[@bib13] The clinical events of interest during the trial were NMIBC recurrence and progression to MIBC. The grade and stage of NMIBC and MIBC were classified using the World Health Organization TNM classification.[@bib14] Patients could have experienced \> 1 recurrence of NMIBC during the follow-up period. Disease progression was defined as the development of MIBC (stage ≥ pT2). Intermediate- and high-risk patients were recommended to undergo single adjuvant intravesical mitomycin C. The intermediate-risk patients were recommended to undergo 6 cycles of once-weekly adjuvant intravesical mitomycin C, and high-risk patients were recommended to undergo induction bacillus Calmette-Guérin with maintenance therapy for 3 years in accordance with international guidelines.[@bib15]^,^[@bib16] Surveillance cystoscopy was performed at 3-month intervals for the first 2 years and then every 6 months for the third and fourth years. In the present report, we focused on the first 3 years of follow-up.

HRQoL, Resource Use, and Cost Data {#sec2.3}
----------------------------------

HRQoL was measured using the EQ-5D-3L, a generic, preference-based measure encompassing 5 dimensions of health (ie, mobility, self-care, usual activities, pain or discomfort, anxiety or depression) and an overall health rating, measured using a visual analog scale.[@bib17] The HRQoL values were generated using reported UK preference "tariffs" for the 243 health states described in the EQ-5D-3L.[@bib18] The values range from 1.0 (perfect health status) to −0.594, with 0 indicating death and negative values reflecting health states considered to be worse than death.[@bib19] The 346 high-risk patients in the trial completed scheduled EQ-5D self-assessments at baseline (trial entry) and at 2, 3, 6, 12, 24, and 36 months of follow-up. The 126 intermediate-risk patients completed scheduled EQ-5D self-assessments at baseline and at 12, 24, and 36 months of follow-up.

The cost analysis used resource use data from questionnaires collected during the trial and took the perspective of the National Health Service and personal social services. The relevant resources used were those related to the diagnosis, treatment, and 3-year follow-up data of the patients included in the BOXIT trial. These included endoscopic investigations, together with the primary, secondary, and palliative care data, and the therapeutic procedures used, including radical cystectomy, chemotherapy, radical radiotherapy, immunotherapy regimens, and intravesical therapy regimens. Missing information relating to the quantity or specific type of treatment administered after a clinical event was assumed to follow usual practice. The unit costs were obtained from a variety of sources ([Supplemental Table 1](#tblS1){ref-type="table"} available in the online version) and inflated to 2017 prices.[@bib20] The costs of inpatient visits were determined using a fixed component relating to the first 2 days of stay, with a marginal component related to any additional days. Care was assumed to have been elective, unless stated otherwise. The total costs were aggregated into years after baseline, with each year estimated by multiplying the number of resources consumed during that period by their respective unit costs and summating.

The HRQoL analysis set consisted of the 316 high-risk patients who had fully completed ≥ 1 EQ-5D questionnaire(s) during the trial. The focus on high-risk patients was to use the most EQ-5D data available and provide the most interpretable estimates of effects, given the small number of MIBC and grade 3 NMIBC events in the intermediate-risk patients and the different EQ-5D follow-up schedules for the 2 risk groups. An analysis that included both risk groups with annual EQ-5D follow-up data was performed as a secondary analysis.

Analysis Methods {#sec2.4}
----------------

The standard approach used to analyze HRQoL and cost data from clinical trials has been to compare these between treatment arms over time to calculate the quality-adjusted life-years (QALYs) and total costs for each patient in the trial.[@bib21] For trials showing no clinically or statistically significant benefit from a new treatment, this method will have little value. However, such trials offer a means of estimating the costs and HRQoL associated with a disease. This can include an exploration of how the HRQoL and costs vary between patients and how the patient characteristics and the clinical events they experience could explain some of this variation.[@bib22]^,^[@bib23] Such analyses can provide valuable information to those assessing the potential value of other new treatments for similar patients.[@bib24]

In the present study, 2 forms of analysis were conducted for both costs and HRQoL. The first analysis was descriptive, with the mean EQ-5D scores calculated at each follow-up period of interest, and the mean costs calculated annually. The patients were grouped in accordance with the types of events experienced during the 3-year follow-up period. The costs were categorized into resource-related groups for comparison. The second analysis was used to establish the effects of an event (ie, NMIBC, MIBC) on each outcome measure. The patients' clinical events were linked to their closest post-event assessment. If multiple NMIBC recurrences had occurred between the EQ-5D or cost assessments, the recurrence with the highest grade was recorded. The effects of the events on the HRQoL and costs were computed using repeated measures regression, controlling for the relevant baseline covariates chosen on the basis of clinical relevance. These included: baseline HRQoL, randomized treatment, history of bladder cancer, patient characteristics (ie, age, body mass index, gender, diabetes), follow-up year, risk group, and interaction terms, as appropriate.

To evaluate the HRQoL and costs, separate generalized estimating equation models were implemented in accordance with reporting guidelines.[@bib25]^,^[@bib26] The model fit, comparison, and selection of the working correlation structure was performed using the quasi-likelihood information criterion.[@bib27]^,^[@bib28] Dependent variables of the annual costs and EQ-5D scores were assumed to follow the gamma and normal distributions, respectively.

Results {#sec3}
=======

Patient Characteristics and Events {#sec3.1}
----------------------------------

Patients experiencing disease recurrence and progression had characteristics similar to those of the patients without disease recurrence and progression. However, modest differences in the rates of diabetes and a history of NMIBC were noted ([Table 1](#tbl1){ref-type="table"}). We assessed whether systematic differences were present between patients with and without missing EQ-5D data at different follow-up points and found that the differences were small ([Supplemental Tables 2](#tblS2){ref-type="table"} and [3](#tblS3){ref-type="table"} available in the online version). This finding supported the assumption from our complete case analysis that the occurrence of missing data was completely at random.Table 1Patient CharacteristicsCharacteristicTotal (n = 472)High Risk (n = 346)Intermediate Risk (n = 126)No Event (n = 321)Progression (n = 29)Recurrence[a](#tbl1fna){ref-type="table-fn"}Overall (n = 138)Grade 1 (n = 36)Grade 2 (n = 62)Grade 3 (n = 46)EQ-5D, baseline0.87 ± 0.150.86 ± 0.170.85 ± 0.220.88 ± 0.150.87 ± 0.130.87 ± 0.160.85 ± 0.200.91 ± 0.110.87 ± 0.14Age, y65.9 ± 9.965.8 ± 10.366.2 ± 8.865.7 ± 10.267.8 ± 7.166.2 ± 9.365.9 ± 10.366.1 ± 7.868.0 ± 7.7BMI, kg/m^2^27.8 ± 4.627.9 ± 4.627.7 ± 4.527.8 ± 4.327.0 ± 4.228.1 ± 5.227.8 ± 6.528.7 ± 5.527.9 ± 4.6Male gender374 (79.2)278 (80.3)96 (76.2)262 (81.6)25 (86.2)102 (73.9)27 (75.0)45 (72.6)33 (71.7)Diabetes42 (8.9)30 (8.7)12 (9.6)23 (7.2)2 (6.9)19 (13.8)6 (16.7)8 (12.9)8 (17.4)NMIBC history159 (34.0)95 (27.8)64 (51.2)94 (29.7)14 (48.3)58 (42.3)17 (47.2)30 (48.4)16 (35.6)Celecoxib236 (50.0)167 (48.3)69 (54.8)164 (51.1)13 (44.8)65 (47.1)22 (61.1)30 (48.4)17 (37.0)Smoking status Never145 (39.6)113 (33.0)32 (25.8)101 (31.8)8 (28.6)42 (30.9)10 (2.8)16 (26.2)18 (40.0) Previous252 (54.1)187 (54.7)65 (52.4)173 (54.4)16 (57.1)70 (51.5)19 (52.8)34 (55.7)21 (46.7) Current69 (14.8)42 (12.3)27 (21.8)44 (13.8)4 (14.3)24 (17.7)7 (19.4)11 (18.0)6 (13.3)ECG result Normal370 (78.6)276 (79.8)94 (75.2)250 (78.1)24 (82.8)109 (79.0)8 (77.8)49 (79.0)37 (80.4) Abnormal101 (21.4)70 (20.2)31 (24.8)70 (21.9)5 (17.2)29 (21.0)28 (77.8)13 (20.1)9 (19.6)[^1][^2][^3]

The recurrence of NMIBC was \> 8 times more common than was progression to MIBC. A total of 233 cases of NMIBC recurrence in 138 patients (29.2%; of all 472 patients) had been recorded during the 3-year follow-up period. In contrast, 29 patients (6.1%) had experienced progression to MIBC (62.1% had undergone subsequent radical surgery). Of the 233 recurrent NMIBC events, 37 were not graded, 46 (9.7%) had experienced ≥ 1 grade 3 NMIBC recurrence (32.6% had undergone subsequent radical surgery), and 62 (13.1%) and 36 (7.6%) patients, respectively, had experienced ≥ 1 grade 2 and grade 1 recurrences (jointly, 4.1% had undergone subsequent radical surgery). Further details of the clinical events in the trial are provided in [Supplemental Table 4](#tblS4){ref-type="table"} (available in the online version).

HRQoL Analysis {#sec3.2}
--------------

The completion rate of the EQ-5D during the 3-year period was 79% (range, 58%-84%) across the points of follow-up. The completion rates after a NMIBC recurrence and progression to MIBC were 60% and 38%, respectively. An overview of the observed mean EQ-5D index scores for high-risk patients and the proportion of events occurring between each EQ-5D follow-up period are presented in [Figure 1](#fig1){ref-type="fig"}. Full details of the HRQoL descriptive results are provided in [Supplemental Tables 5](#tblS5){ref-type="table"} and [6](#tblS6){ref-type="table"} (available in the online version).Figure 1EQ-5D Scores for High-risk Patients for Each Event-related Subgroup and Associated Proportion of Events in Each Follow-up Point During 3 Years of Follow-up. The *x*-Axis Represents Time in Months After Baseline With Categories and Their Distance Solely Indicative of Trial Follow-up and Not Equating to the Length of Time Between Intervals

The set of subgroups comprising patients who had experienced ≥ 1 of the specified clinical events during the 3-year follow-up period or had experienced no event is presented in [Figure 1](#fig1){ref-type="fig"}. These findings suggest that NMIBC recurrence and MIBC progression could be associated with deterioration in HRQoL at specific points. The variation in HRQoL at specific follow-up points was largely driven by the events experienced by the patients. In contrast, the variation in HRQoL between the follow-up points was related to the underlying within-patient variations, the nonuniform distribution of events over time, and the sampling error, exacerbated by partitioning modestly sized subgroups. A comparison of the EQ-5D dimensions stratified by the event-related subgroup found greater proportions of patients reporting problems with pain or discomfort and undertaking usual activities when experiencing a grade 3 recurrence or MIBC progression compared with no events during the 3-year follow-up period ([Supplemental Figure 1](#figS1){ref-type="fig"} available in the online version).

The statistically significant effects of clinical events on HRQoL in terms of the estimated decrements and mean health-state values are listed in [Table 2](#tbl2){ref-type="table"}. Progression to MIBC and NMIBC grade 3 recurrence were associated with predicted mean decrements in HRQoL of −0.10 (95% confidence interval, −0.17 to −0.03) and −0.08 (95% confidence interval, −0.13 to −0.03), respectively (*P* \< .01). In contrast, the recurrence of NMIBC grade 1 and grade 2 was associated with positive, but statistically insignificant (*P* \> .1), increments in HRQoL compared with patients without cancer.Table 2Estimated Statistically Significant Effects on HRQoL and Associated Health State Values From Clinical Events (High-risk Patients Only)VariableEstimated HRQoL Decrement[a](#tbl2fna){ref-type="table-fn"}Estimated Health State Value[a](#tbl2fna){ref-type="table-fn"}No eventNA0.84606 (0.83292 to 0.85921)NMIBC recurrence (grade 3)−0.08306[b](#tbl2fnb){ref-type="table-fn"} (−0.13379 to −0.03233)0.76300 (0.71178 to 0.81422)MIBC progression−0.09909[b](#tbl2fnb){ref-type="table-fn"} (−0.17256 to −0.02561)0.74698 (0.67309 to 0.82087)[^4][^5][^6][^7]

The secondary analysis showed that introducing an interaction term into the regression analysis revealed that patients with grade 3 NMIBC recurrence in the first year experienced larger decrements in HRQoL (−0.11) compared with those with recurrence in subsequent years (−0.04). The small numbers precluded the same analysis for MIBC progression. Including both high- and intermediate-risk patients in the analysis using only the annual EQ-5D assessment data generated NMIBC recurrence estimates closer to 0 for all grades, with only MIBC events resulting in a statistically significant decrement in HRQoL (*P* \< .05). Irrespective of the bladder cancer grade or stage, radical cystectomy was associated with a −0.17 decrement in HRQoL. All regression results and primary variance--covariance matrices are presented in [Supplemental Table 10](#tblS10){ref-type="table"}, [Supplemental Table 11](#tblS11){ref-type="table"}, [Supplemental Table 12](#tblS12){ref-type="table"}, [Supplemental Table 13](#tblS13){ref-type="table"}, [Supplemental Table 7](#tblS7){ref-type="table"}, [Supplemental Table 8](#tblS8){ref-type="table"}, [Supplemental Table 9](#tblS9){ref-type="table"} (available in the online version).

Cost Analysis {#sec3.3}
-------------

The mean costs per patient for each type of care ([Supplemental Table 1](#tblS1){ref-type="table"} available in the online version), annually and in total, are reported in [Figure 2](#fig2){ref-type="fig"}. The mean cost of treatment for a patient with NMIBC was £4854 in the first year, with a total cost of £8735 over three years. These results suggest that the costs decline over time, with mean costs of £1496 in year 3. Endoscopic surveillance was the principal cost driver, accounting for \> 52% of the total costs and representing a high proportion in years 2 (£1384 of £2386) and 3 (£835 of £1496). These estimates resulted in a 3-year total cost for the UK NMIBC bladder cancer cohort diagnosed in 2015 at \~£66.14 million, assuming that 74.5% of the 10,171 UK bladder cancer cases were NMIBC.[@bib2]^,^[@bib29]Figure 2Mean Costs per Patient Over Time Stratified by Resource Category for Intermediate- and High-risk Patients

The effect of the clinical events on annual costs is shown in [Figure 3](#fig3){ref-type="fig"}, which indicated that MIBC progression and all grades of NMIBC recurrence led to increased costs. Higher grades of NMIBC were associated with higher costs, with grade 3 recurrence events necessitating more intensive therapy and closer surveillance. Progression to MIBC was associated with the greatest cost increment, with a £5407 increase in the expected annual cost per patient, again reflecting the more intensive therapy. Additionally, the treatment and surveillance of high-risk patients were associated with a £1968 increase in mean costs in the first year, although the costs had declined to £457 and £74 in years 2 and 3, respectively. The predicted mean costs per patient by year, event status, and risk group are shown in [Table 3](#tbl3){ref-type="table"}.Figure 3Estimated Mean Change in Annual Cost per Patient Associated With Clinical Events (95% Confidence Intervals Shown by Vertical Bars) From a Multivariate Longitudinal Panel Cost-related Analysis Controlling for Treatment, Patient Characteristics, Risk Group, Annual Time Dummies, Bladder Cancer Events, and InteractionsTable 3Estimated Patient Costs Across Time, Risk Group, and Event Status[a](#tbl3fna){ref-type="table-fn"}Risk GroupYearNo Bladder CancerNMIBC RecurrenceMIBC ProgressionGrade 1Grade 2Grade 3High1£4796£6014£6472£8753£10,3742£2363£3581£4039£6320£79403£1387£2605£3063£5344£6964Intermediate1£2828£4046£4505£6785£84062£1907£3125£3583£5864£74843£1314£2532£2990£5271£6891[^8][^9]

Discussion {#sec4}
==========

Published economic evaluations of treatments for bladder cancer have lacked robust estimates of clinical effects on HRQoL and costs.[@bib30]^,^[@bib31] Furthermore, clinicians should understand the consequences of clinical events on patients' well-being and the health service costs. The present study has provided new evidence on the costs and HRQoL associated with NMIBC occurrence, recurrence, and progression to MIBC, supporting future clinical and economic evaluations. Our findings suggest that NMIBC will have an average cost of £8735 during a 3-year period, with cases of grade 1, 2, and 3 NMIBC recurrences and progression to MIBC associated with £1218, £1677, £3957, and £5407 increases in annual costs, respectively. In addition, grade 3 recurrence and progression to MIBC were associated with statistically significant decrements in HRQoL (−0.08 and −0.10, respectively).

Singer et al[@bib32] reported that patients with bladder cancer, whether muscle invasive or not, will experience significant and clinically relevant deteriorations in HRQoL. Little evidence has contradicted the idea that patients with MIBC will experience a significant health burden; however, the same cannot necessarily be said for those with NMIBC. The commonly reported NMIBC morbidities have included mental health effects at diagnosis, physical discomfort, sexual problems, and urinary symptoms.[@bib33], [@bib34], [@bib35] However, these have rarely translated into reductions in longer term health outcomes and, in some cases, have not been recorded at all.[@bib9]^,^[@bib36] It has been suggested that patients might become "accustomed" to NMIBC and its related management, accepting recurrences as a part of their lives.[@bib10] The evidence presented from the BOXIT trial has offered some additional support for this view, but suggests that not all cases of NMBIC recurrence should be considered equal. Based on the recommended NMIBC surveillance guidelines, our results suggest that the negative effect of a NMIBC recurrence on HRQoL will be concentrated within the high-grade strata (grade 3), especially in the first year after the diagnosis. Furthermore, no evidence of negative HRQoL outcomes from grade 1 or 2 NMIBC recurrences was found. This might, at least in part, be explained by the low rates of radical surgery observed for grade 1 and 2 NMIBC recurrences. The results from supplementary analyses have supported these findings, with the use of cystectomy a large and significant predictor of HRQoL status. In addition, the patient groups with the highest rates of radical surgery (for grade 3 recurrence and progression) were most likely to report related problems with pain or discomfort and undertaking usual activities. A fuller understanding of the mechanisms behind these findings requires further prospective research.

Sangar et al,[@bib37] estimated that the UK cost in 2001 to 2002 for the diagnosis, treatment, and 5-year follow-up of each bladder cancer case was £55.39 million, at a mean cost of £8349.20. Allowing for inflation and the different follow-up periods, their results are similar to those from the present study. To put this into context, it would be less costly per patient to treat stage 2 colon, rectal, and non--small-cell lung cancer in the United Kingdom.[@bib38] The results from our analysis compliment those from the earlier study, showing the prominent role of endoscopic surveillance in driving the costs, which has remained the primary target for innovation in bladder cancer management.[@bib5]^,^[@bib39]^,^[@bib40] Optimizing surveillance has also remained a research priority. Less costly and noninvasive urinary biomarkers represent an attractive option; however, to date, no commercially available test has the diagnostic accuracy to replace cystoscopy because patients and physicians require a test with high sensitivity before widespread acceptance.[@bib41], [@bib42], [@bib43] Similar to others, we found that progression to MIBC will be associated with higher costs for intermediate- and high-risk patients.[@bib44]

The relatively large sample size, prospective study design, and the use of a validated HRQoL instrument represent the strengths of the present study. To the best of our knowledge, this is the first study to estimate both the mean and the marginal HRQoL and the cost effects across multiple grades and stages of bladder cancer. However, the present study had several important limitations. Despite the BOXIT protocol remaining representative of current UK guidelines (other than celecoxib treatment), differences between the BOXIT trial and current clinical practice have occurred (eg, the European Association of Urology now recommends bacillus Calmette-Guérin instillations for intermediate-risk patients and have revised the definitions of risk[@bib45]). In addition, the trial's exclusion criteria could have limited the generalizability of our study, with results applicable to a cohort healthier than what might be observed in clinical practice. With respect to HRQoL, the EQ-5D is a generic measure of health outcomes suitable to assess the value of healthcare interventions across different disease areas. The EQ-5D is the preferred instrument of the National Institute for Health and Care Excellence for cost-effectiveness analysis. Although the measure showed important differences between the patient subgroups, further research could assess whether the EQ-5D is sufficiently sensitive to detect important clinical changes in patients with bladder cancer. Regarding the study findings, the true negative repercussions of MIBC might differ from those reported because the number of patients who progressed to MIBC was relatively small because BOXIT trial was powered to investigate the interval to the first recurrence. This, coupled with the low postprogression EQ-5D response rate, resulted in uncertain estimates and might lead to overestimates of the HRQoL because patients with relatively poor health outcomes after the development of MIBC might be less likely to complete the EQ-5D. Moreover, the increasingly protracted EQ-5D follow-up periods meant that the clinical events in the study became progressively distant from completion of the EQ-5D. Whether improvements in the reported postevent HRQoL outcomes over time stemmed from the true underlying dynamics of bladder cancer or had resulted only from time-related disparities between the event and the follow-up evaluation remains to be determined.

The costs could have been underestimated for several reasons. First, our analysis of the effect of the events on the annual costs neglected the potential dynamics and spillover effects between the evaluation periods. Bladder cancer events will inevitably prompt immediate resource use; however, the costs incurred from stricter surveillance and the greater risk of related events will be realized further into the future. Understanding these dynamics requires a more detailed collection of the resource use data and remains a potential avenue for further research. Second, the assumption that the treatments were elective could, again, have underrepresented the costs. Third, the protracted and persistent nature of bladder cancer has far broader cost effects than those incurred only by the NHS within 3 years. A wider perspective would give a more comprehensive account of the earnings, productivity, and time lost by patients with bladder cancer and their informal caregivers.

Conclusion {#sec5}
==========

The results from our analysis of the BOXIT trial data suggest that patients with NMIBC will experience decrements in HRQoL, with significant costs imposed in the event of disease recurrence or progression, and the costs increasing with the abnormality and invasiveness of the lesion.

Clinical Practice Points {#sec5.1}
------------------------

•A need exists to evaluate the costs and HRQoL implications of bladder cancer and its recurrence and progression to assess the disease burden, inform resource allocation decisions, and aid further research.•It has been shown that NMIBC will be associated with considerable costs in the United Kingdom and that patients will experience significant decrements in HRQoL with progression to MIBC; however, the effect from NMIBC recurrence is less clear.•In our study, we reported both the mean and the marginal UK HRQoL and cost effects across multiple grades and stages of bladder cancer for patients with NMIBC and found significant decrements in HRQoL related to grade 3 recurrence and progression to MIBC; the cost effects increased with the lesion\'s abnormality and invasiveness.•The evidence presented from the BOXIT trial suggests that not all cases of NMBIC recurrence should be considered equal with respect to the effects on patient HRQoL or the consequent healthcare costs.•The results from the present study could help to lay the foundation for future related burden of disease studies and cost-effectiveness analyses.
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Supplemental Data {#appsec1}
=================

Supplemental Figure 1EQ-5D Responses Stratified by Dimension and Severity Level for High-risk Patients for Each Event-related Subgroup During 3 Years of Follow-up. The Number Indicates the Maximum Number of Observations Recorded of an EQ-5D Dimension for a Given Event-related Subgroup (eg, ≤ 119 Recordings Were Made of an EQ-5D Dimension for Patients Who Had Experienced a Grade 2 Recurrence During the 3-year Follow-up Period)Supplemental Table 1Unit CostsCareUnit Costs[a](#tblS1fna){ref-type="table-fn"}SourcePrimary carePSSRU health and social care, 2017[@bib20] GP home visit£86 Specialist nurse home visit£57 General practice surgery visit, GP£32 General practice surgery visit (nurse)£10Secondary careNHS schedule reference costs 2016-2017[@bib46] Outpatient attendance£108TOA: urology outpatient attendance (service code, 101) Inpatient attendance£820EL: minor bladder procedures, age ≥ 19 y (HRG code, LB15E) Inpatient excess days£397EL XS: intermediate open bladder procedures (HRG code, LB12Z)Palliative care[b](#tblS1fnb){ref-type="table-fn"}£12,968NICE technology assessment January 2010[@bib47]SurveillanceNICE technology assessment January 2010[@bib47] Flexible cystoscopy£449 Rigid cystoscopy£1176Intravesical/immunotherapy Mitomycin instillation£80British National Formulary 2018 Bacillus Calmette-Guérin instillation£101NICE technology assessment January 2010[@bib47]Radical surgery Cystectomy£9973Total HRGs: cystectomy with urinary diversion and reconstruction (code, LB39C/LB39D) Lobectomy£6601NICE clinical guideline 121 (2011)[@bib48] Nephroureterectomy£6471Complex, open or laparoscopic, kidney or ureter procedures, with CC score 0-1 (HRG code, LB60F) Renogram£256Renogram, age ≥ 19 y (HRG code, RN25A)Chemotherapy/radiotherapy[c](#tblS1fnc){ref-type="table-fn"} Radical radiotherapy£1156NICE technology assessment January 2010[@bib47] Gemcitabine, cisplatin£169eMit drug unit costs and London Cancer Network administration schedules Gemcitabine, carboplatin£232eMit drug unit costs and London Cancer Network administration schedules 5-FU, MMC£104eMit drug unit costs and London Cancer Network administration schedules Carboplatin, etoposide£173eMit drug unit costs and London Cancer Network administration schedules[^10][^11][^12][^13]Supplemental Table 2Summary Statistics Comparison: Missing and Nonmissing EQ-5D Data Collection[a](#tblS2fna){ref-type="table-fn"}VariableMissing ValuesNonmissing ValuesnMeannMeanMonth 2 Age18765.1928566.38 BMI18027.7126627.89 Gender18775%28582% Never smoked4826%9734% Previous smoker9753%15555% Current smoker3921%3011% ECG result18623%28521% Celecoxib18752%28548% Diabetes18611%2858% History18344%28427%Month 3 Age18565.4128766.26 BMI17927.7726727.85 Gender18575%28782% Never smoked4424%10135% Previous smoker9753%15555% Current smoker4123%2810% ECG result18421%28722% Celecoxib18554%28747% Diabetes18411%2878% History18146%28627%Month 6 Age19665.2727666.40 BMI18927.6625727.93 Gender19674%27683% Never smoked5026%9535% Previous smoker10353%14955% Current smoker4021%2910% ECG result19521%27622% Celecoxib19653%27648% Diabetes19512%2767% History19246%27526%Month 12 Age12565.6734766.02 BMI12027.9132627.78 Gender12578%34780% Never smoked3125%11433% Previous smoker6654%18654% Current smoker2521%4413% ECG result12419%34722% Celecoxib12552%34749% Diabetes1249%3479% History12234%34534%Month 24 Age16366%30966.03 BMI15527.6529127.91 Gender16379%30980% Never smoked4226%10334% Previous smoker9056%16253% Current smoker2818%4113% ECG result16216%30924% Celecoxib16352%30949% Diabetes16210%3098% History16036%30733%Month 36 Age19166.2128165.73 BMI18327.6226327.95 Gender19179%28179% Never smoked4725%9835% Previous smoker10053%15255% Current smoker4122%2810% ECG result19020%28122% Celecoxib19153%28148% Diabetes1909%2819% History18836%27933%[^14][^15]Supplemental Table 3Summary Statistics Comparison: Missing and Nonmissing Costs[a](#tblS3n1){ref-type="table-fn"}VariableMissing ValuesNonmissing ValuesnMeannMeanYear 1 Age2569.1644765.75 BMI2327.2942327.85 Gender2580%44779% Never smoked624%14532% Previous smoker1352%23953% Current smoker624%6314% ECG result248%44722% Celecoxib2552%44750% Diabetes2413%4429% History2352%44433%Year 2 Age3068.5744265.75 BMI2826.9141827.88 Gender3080%44279% Never smoked723%14433% Previous smoker1963%22353% Current smoker413%6515% ECG result2914%44222% Celecoxib3047%44250% Diabetes2910%4429% History2839%43934%Year 3 Age4768.0942565.69 BMI4527.1540127.89 Gender4774%42580% Never smoked1123%14033% Previous smoker2655%22653% Current smoker1021%5914% ECG result4611%42523% Celecoxib4743%42550% Diabetes467%4259% History4542%42233%[^16][^17]Supplemental Table 4Trial Events[a](#tblS4fna){ref-type="table-fn"}VariableTrial Event, nMonth 2Month 3Month 6Month 12Month 24Month 36Total EventsTotal PatientsHRIRHRIRHRIRHRIRHRIRHRIRMIBC progression0020508091402929NMIBC recurrence32663820193223442218233138Recurrence grade22643514162917371717196121 Unknown00000020001033 Grade 1010047311514095436 Grade 2103497415721778562 Grade 311302207352915446[^18][^19]Supplemental Table 5Observed EQ-5D Scores From the BOXIT Trial for High-risk PatientsEQ-5DEQ-5D Event-Specific ScoresBaselineMonth 2Month 3Month 6Month 12Month 24Month 36Average Mean ± SD0.86 ± 0.170.84 ± 0.200.85 ± 0.180.86 ± 0.180.85 ± 0.190.83 ± 0.190.85 ± 0.19 Patients, n309284286274250223205No event Mean ± SD0.88 ± 0.150.86 ± 0.200.87 ± 0.150.88 ± 0.160.86 ± 0.170.85 ± 0.160.86 ± 0.18 Patients, n224210209209297181168Progression Mean ± SD0.82 ± 0.230.79 ± 0.230.76 ± 0.220.78 ± 0.260.75 ± 0.260.60 ± 0.300.71 ± 0.35 Patients, n2826281915107Recurrence Mean ± SD0.84 ± 0.200.83 ± 0.200.82 ± 0.210.81 ± 0.210.82 ± 0.210.79 ± 0.250.83 ± 0.20 Patients, n71626456453533Recurrence grade 1 Mean ± SD0.90 ± 0.110.85 ± 0.120.88 ± 0.140.86 ± 0.110.93 ± 0.200.81 ± 0.210.83 ± 0.33 Patients, n8787444 2 Mean ± SD0.88 ± 0.140.90 ± 0.100.89 ± 0.130.86 ± 0.200.84 ± 0.140.70 ± 0.320.78 ± 0.78 Patients, n23212120171410 3 Mean ± SD0.85 ± 0.170.82 ± 0.210.79 ± 0.230.75 ± 0.220.79 ± 0.260.77 ± 0.270.80 ± 0.22 Patients, n3631332720166[^20]Supplemental Table 6Observed EQ-5D Scores From the BOXIT Trial for Intermediate- and High-Risk PatientsEQ-5DEQ-5D Event-Specific ScoresBaselineMonth 12Month 24Month 36Average Mean ± SD0.86 ± 0.190.85 ± 0.200.83 ± 0.200.85 ± 0.20 Patients, n410347309281No event Mean ± SD0.87 ± 0.160.86 ± 0.180.84 ± 0.180.85 ± 0.20 Patients, n275244224209Progression Mean ± SD0.82 ± 0.230.71 ± 0.280.66 ± 0.550.71 ± 0.35 Patients, n2916117Recurrence Mean ± SD0.85 ± 0.210.84 ± 0.230.84 ± 0.240.87 ± 0.19 Patients, n121957868Recurrence grade 1 Mean ± SD0.81 ± 0.290.77 ± 0.310.80 ± 0.300.87 ± 0.26 Patients, n28242118 2 Mean ± SD0.91 ± 0.120.88 ± 0.160.84 ± 0.260.88 ± 0.19 Patients, n54484133 3 Mean ± SD0.86 ± 0.170.80 ± 0.270.77 ± 0.290.83 ± 0.21 Patients, n41262120[^21]Supplemental Table 7Primary HRQoL RegressionVariableCoefficientSEz*P* \> z95% CIEQ5D score baseline0.59679240.040653214.68.0000.5171136 to 0.6764713Patient gender0.05213570.01795872.90.0040.0169372 to 0.0873341Age category, y 50-59−0.01873660.0338184−0.55.580−0.0850194 to 0.0475462 60-69−0.00399310.0318242−0.13.900−0.0663674 to 0.0583812 70-79−0.01084620.0331665−0.33.744−0.0758513 to 0.0541589 \> 80−0.02431560.0396575−0.610.540−0.1020428 to 0.0534116BMI category Overweight−0.01003580.0166613−0.600.547−0.0426913 to 0.0226198 Obese−0.00695840.0182376−0.380.703−0.0427036 to 0.0287867 Morbidly obese−0.06529680.0651534−1.000.316−0.1929952 to 0.0624015Smoking status Previous−0.00338880.0148166−0.230.819−0.0324288 to 0.0256512 Current−0.00695760.0239007−0.290.771−0.0538022 to 0.039887ECG result−0.00570310.016846−0.340.735−0.0387207 to 0.0273145Celecoxib treatment−0.00106740.0136832−0.080.938−0.0278859 to 0.0257511Diabetes−0.09894090.0252237−3.920.000−0.1483784 to −0.0495034TCC history−0.0154770.0155777−0.990.320−0.0460086 to 0.0150547Year 2−0.02508810.0103193−2.430.015−0.0453134 to −0.0048627 3−0.01074930.0102873−1.040.296−0.0309119 to 0.0094134Tumor recurrence Unknown0.03348090.08233010.410.684−0.1278831 to 0.1948449 Grade 10.062 03080.05558151.120.264−0.046907 to 0.1709685 Grade 20.05180030.03392021.530.127−0.014682 to 0.1182826 Grade 3−0.08306120.0258832−3.210.001−0.1337914 to −0.0323311Progression−0.09908530.037488−2.640.008−0.1725605 to −0.0256102Progression history0.00438920.05163790.080.932−0.0968193 to 0.1055976Constant0.32188220.04893216.580.0000.225977 to 0.4177873[^22]Supplemental Table 8Primary HRQoL Regression Including Time and Event InteractionEQ-5D ScoreCoefficientSEz*P* \> z95% CIEQ-5D score baseline0.59739070.040768314.65.0000.5174862 to 0.6772952Patient gender0.05304370.01802072.94.0030.0177238 to 0.0883636Age category, y 50-59−0.0200570.0339243−0.59.554−0.0865473 to 0.0464333 60-69−0.00601090.03192 99−0.19.851−0.0685923 to 0.0565705 70-79−0.01133830.0332657−0.34.733−0.0765379 to 0.0538613 \>80−0.02744070.0397877−0.69.490−0.1054232 to 0.0505419BMI category Overweight−0.010430.0167119−0.62.533−0.0431847 to 0.0223247 Obese−0.00738030.0183151−0.40.687−0.0432771 to 0.0285166 Morbidly obese−0.06296690.0653087−0.96.335−0.1909695 to 0.0650357Smoking status Previous−0.00292970.0148631−0.20.844−0.0320609 to 0.0262014 Current−0.00803740.0239813−0.34.738−0.05504 to 0.0389651ECG result−0.00520070.0168996−0.31.758−0.0383233 to 0.0279219Celecoxib treatment−0.00047860.0137258−0.03.972−0.0273807 to 0.0264235Diabetes−0.10001320.0253062−3.95.000−0.1496125 to −0.0504139TCC history−0.01573220.0156268−1.01.314−0.0463602 to 0.0148957Tumor recurrence & year interactionsNo cancer & \> year 1−0.02098440.0089722−2.34.019−0.0385696 to −0.0033992 Unknown & year 10.05068890.11563770.44.661−0.1759568 to 0.2773346 Unknown & \> year 10.00382890.11594980.03.974−0.2234286 to 0.2310864 Grade 1 & year 1−0.0286710.0896046−0.32.749−0.2042929 to 0.1469509 Grade 1 & \> year 10.09077410.07068221.28.199−0.0477605 to 0.2293087 Grade 2 & year 10.02841850.04689970.61.545−0.0635031 to 0.1203402 Grade 2 & \> year 10.06907650.04869861.42.156−0.026371 to 0.1645239 Grade 3 & year 1−0.10964230.0317785−3.45.001−0.171927 to −0.0473577 Grade 3 & \> year 1−0.04293080.0428694−1.00.317−0.1269532 to 0.0410917Progression−0.09378180.0373684−2.51.012−0.1670225 to −0.0205412Progression history0.00532120.0513640.10.917−0.0953503 to 0.1059927Constant0.32281220.04907956.58.0000.2266181 to 0.4190063[^23]Supplemental Table 9HRQoL Regression With Intermediate- and High-Risk Patients and Annual EQ-5DEQ-5D ScoreCoefficientSEz*P* \> z95% CIEQ-5D score baseline0.62224120.044082414.12.0000.5358413 to 0.7086411Risk group−0.02217770.0181653−1.22.222−0.0577811 to 0.0134256Patient gender0.03440060.01926681.79.074−0.0033617 to 0.0721629Age category, y 50-59−0.04219940.0414963−1.02.309−0.1235307 to 0.039132 60-69−0.0512390.0393116−1.30.192−0.1282882 to 0.0258103 70-79−0.06004820.0411742−1.46.145−0.1407482 to 0.0206518 \>80−0.07265050.0482603−1.51.132−0.1672389 to 0.0219379BMI category Overweight−0.02215570.018897−1.17.241−0.0591931 to 0.0148818 Obese−0.03811210.0206114−1.85.064−0.0785097 to 0.0022855 Morbidly obese−0.106480.0743021−1.43.152−0.2521095 to 0.0391495Smoking status Previous0.01022640.01714810.60.551−0.0233833 to 0.0438361 Current−0.05475930.0252457−2.17.030−0.1042399 to −0.0052786ECG result−0.03820360.0187138−2.04.041−0.074882 to −0.0015251Celecoxib treatment−0.00812240.0155085−0.52.600−0.0385186 to 0.0222737Diabetes−0.06276960.027287−2.30.021−0.116251 to −0.0092881TCC history−0.01777080.016869−1.05.292−0.0508335 to 0.0152919Year 2−0.02057430.009907−2.08.038−0.0399916 to −0.001157 3−0.01870820.0106461−1.76.079−0.0395742 to 0.0021579Tumor recurrence Unknown0.06160680.09575210.64.520−0.1260638 to 0.2492774 Grade 1−0.0059750.0317292−0.19.851−0.068163 to 0.056213 Grade 20.00197650.02218780.09.929−0.0415108 to 0.0454638 Grade 3−0.04346080.0277767−1.56.118−0.0979022 to 0.0109806Progression−0.10206260.0428498−2.38.017−0.1860467 to −0.0180785Progression history−0.04341590.0623099−0.70.486−0.1655411 to 0.0787093Constant0.40076730.05964216.72.0000.2838709 to 0.5176637[^24]Supplemental Table 10Base Case HRQoL Regression Including Cystectomy as a CovariateEQ-5D ScoreCoefficientSEz*P* \> z95% CIEQ-5D score baseline0.6361080.037774416.84.0000.5620715 to 0.7101444Patient gender0.04778770.01638282.92.0040.0156781 to 0.0798973Age category, y 50-59−0.02887820.0346037−0.83.404−0.0967001 to 0.0389438 60-69−0.0375650.0327225−1.15.251−0.1016999 to 0.0265698 70-79−0.04643120.0342036−1.36.175−0.1134689 to 0.0206066 \>80−0.0521820.0399786−1.31.192−0.1305387 to 0.0261747BMI category Overweight−0.01770770.0156904−1.13.259−0.0484604 to 0.0130449 Obese−0.01509460.0172463−0.88.381−0.0488967 to 0.0187074 Morbidly obese−0.02733590.0608352−0.45.653−0.1465707 to 0.0918989Smoking status Previous0.00641220.0142 6370.45.653−0.0215443 to 0.0343686 Current−0.02954270.0214073−1.38.168−0.0715001 to 0.0124148ECG result−0.02157470.0157273−1.37.170−0.0523997 to 0.0092503Celecoxib treatment−0.00816320.0129252−0.63.528−0.0334961 to 0.0171696Diabetes−0.08815470.0233651−3.77.000−0.1339494 to −0.0423601TCC history−0.0221550.0137706−1.61.108−0.049145 to 0.0048349Year 2−0.01742810.0085872−2.03.042−0.0342587 to −0.0005975 3−0.01618010.0090078−1.80.072−0.033835 to 0.0014749Cystectomy−0.16768280.0382576−4.38.000−0.2426664 to −0.0926992Constant0.33409470.04769717.00.0000.24061 to 0.4275793[^25]Supplemental Table 11Costing RegressionTotal CostsCoefficientSEz*P* \> z95% CITumor recurrence Unknown1517.2231729.0410.88.380−1871.636 to 4906.082 Grade 11217.438415.96332.93.003402.1653 to 2032.711 Grade 21676.051385.98314.34.000919.5377 to 2432.564 Grade 33956.667829.37514.77.0002331.122 to 5582.212Risk group, high risk1967.914311.4946.32.0001357.397 to 2578.431Year 2−921.3536251.7046−3.66.000−1414.686 to −428.0217 3−1514.189233.9928−6.47.000−1972.806 to −1055.571Risk group & year High risk & year 2−1511.85343.8087−4.40.000−2185.702 to −837.997 High risk & year 3−1894.898319.9745−5.92.000−2522.036 to −1267.759Progression5406.9381400.3353.86.0002662.332 to 8151.544Progression history2269.138806.85282.81.005687.7356 to 3850.54TCC history91.5351891.503931.00.317−87.80923 to 270.8796Patient gender162.3912104.3481.56.120−42.12716 to 366.9096Diabetes−67.09895147.0358−0.46.648−355.2838 to 221.0859Celecoxib treatment−103.150490.55783−1.14.255−280.6405 to 74.33965Toxicity Mild condition190.4007173.78121.10.273−150.2041 to 531.0055 Moderate condition171.735300.59230.57.568−417.415 to 760.885Celecoxib treatment & toxicity interaction Interaction 1 & Mild condition153.2397242.2950.63.527−321.6498 to 628.1292 1 & Moderate condition390.0575387.77381.01.314−369.9651 to 1150.08Age, y 50-5936.85634193.84370.19.849−343.0704 to 416.7831 60-6962.7073177.39310.35.724−284.9767 to 410.3913 70-79−78.92821182.5277−0.43.665−436.676 to 278.8195 \>8059.02592226.99820.26.795−385.8824 to 503.9342BMI Overweight207.679595.780292.17.03019.95362 to 395.4054 Obese258.0722113.32262.28.02335.96402 to 480.1804 Morbidly obese1257.968623.30532.02.04436.31178 to 2479.624Smoking status Previous−57.2001197.19538−0.59.556−247.6996 to 133.2993 Current−241.9663122.4042−1.98.048−481.8741 to −2.058529Constant2348.796305.06767.70.0001750.875 to 2946.718[^26]Supplemental Table 12Variance--Covariance Matrix Base Case HRQoL Regression AnalysisVariableEQ-5D BaseGenderAge, yBMISmokingECG ResultCelecoxibDiabetesHistoryYearGradeProgressionProgression HistoryConstant50-6060-7070-80\>80OverweightObeseMorbidly ObesePreviousCurrent23Unknown123EQ-5D baseline0.00165Gender0.00000.0003Age, y 50-600.0000−0.00010.0011 60-70−0.0001−0.00010.00090.0010 70-800.0000−0.00010.00090.00090.0011 \>80−0.0001−0.00010.00090.00090.00100.0016BMI Overweight0.00000.00000.00000.00000.0000−0.00010.0003 Obese0.00010.00000.00000.00000.00000.00000.00020.0003 Morbidly obese−0.00010.0000−0.0001−0.00010.00000.00000.00020.00020.0042Smoking Previous0.00000.0000−0.0001−0.00010.00000.00000.00000.0000−0.00010.0002 Current0.0001−0.00010.00000.00000.00010.00000.00000.0000−0.00010.00010.0006ECG result0.00000.00000.0000−0.0001−0.0001−0.00020.00000.00000.00000.00000.00000.0003Celecoxib0.00000.00000.00000.00010.00000.00000.00000.00000.00000.0000−0.00010.00000.0002Diabetes0.00010.00000.0000−0.0001−0.0001−0.00010.00000.0000−0.00020.00000.00000.00000.00000.0006TCC history0.00010.00000.00000.00000.00000.00000.00000.00000.00010.00000.00000.00000.00000.00000.0002Year 20.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0001 30.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0001Grade Unknown0.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0068 10.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0031 20.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0012 30.00000.00000.00000.00000.00000.00000.00000.0000−0.00010.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0007Progression0.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000−0.00010.0014Progression history0.00000.00000.00000.0000−0.00010.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00000.00040.0027Constant−0.0014−0.0002−0.0008−0.0008−0.0008−0.0008−0.0001−0.00020.00000.0000−0.00010.0000−0.0001−0.0001−0.00010.00000.00000.00000.00000.00000.00000.00000.00000.0024[^27]Supplemental Table 13Variance--Covariance Matrix Base Case Cost Regression AnalysisVariableTumor GradeHRYear\#YearProgressionProgression HistoryTCC HistoryGenderDiabetesCelecoxibToxicity\#ToxicityAge, yBMISmokingConstant\
Unknown1232323MildModerateMildModerate50-6060-7070-80\>80OverweightObeseMorbidly ObesePreviousCurrentTumor grade Unknown2989584 13197.897173025.4 2455.00075153.004148982.9 34751.8881440.315766.639687863.1HR−12,708.17947.3946233.751−12,978.797,028.53Year 2128.55322513.2265118.3162360.68345,236.9163,355.2 3417.79226185.7739399.3753398.29546,386.9247,142.2954,752.65HR \# year 212,903.19−2631.28−1898.0313,670.3−92,607.2−61,490.2−44,871.9118204.4HR \# year 310,099.37−5412.12−5798.3212,242.9−94,413.4−44,807.9−51,859.691,808.03102383.7Progression3772.37167.20135−12,774.8−87,906.4−11,840.8−1096.95−1184.226543.2210,696.111,960,938Progression history3597.378131.96451131.3083651.328−756.922429.535937.94244−3169.66−1512.3147,298.56651011.4TCC history−3973.36177.3514−249.955−618.6221794.413201.794446.6992−80.3491−176.578−1414.4−2551.178372.969Patient gender−2929.97−77.8528500.8079550.0644−184.652924.89611028.345−228.396−256.491−934.697−1450.44634.907510,888.51Diabetes174.1897458.7002−786.564−1579.561.5317793.05056−59.2129−127.267−313.9611281.531−1474.4518.0848588.371121,619.53Celecoxib2048.935402.4205−98.0007920.2471216.8488−36.8882−714.75681.53749647.6306231.6324515.0038−10.0378−759.794−1101.228200.721Toxicity Mild−600.194429.0679321.6055−73.1877630.13644588.0255054.176−527.603−608.46713.45951786.313298.78082207.895−454.8883779.81330,199.89 Moderate2383.184−2263.531663.6322924.52−1789.756931.3816671.093103.26723430.7164155.0161639.651135.82651061.755−97.26493874.0486976.89690,355.71Celecoxib \# mild438.1648−1952.97601.5322−1065.34−393.143−880.25427.7197−287.85−203.163−1276.02−266.424226.7488−1008.46427.0523−7417.36−29,182.4−5234.2758,706.88Celecoxib \# moderate−578.645204.5142−1252.18−3234.893614.205−463.2311200.66−1325.14−5724.77−4619.99−150.712−435.541−60.541550.1123−7471.91−5457.64−88,242.49219.409150368.5Age, y 50-60−461.326−1297.4−2167.35−219.887877.5002−383.189−780.626−62.6462536.89911446.35−632.30754.15569−388.29−844.3221911.414−315.633−16.8047−1357.87−284.00337,575.4 60-70−760.247−565.579−1189.19−1265.141569.057−532.382−836.33780.84493565.3626−535.485−3198.85294.7149−1511.36−2402.452058.851−920.176−519.123−1076.13−61.978827,048.931,468.3 70-80−3417.03−643.19−422.365−493.5631144.489−680.322−1062.5332.89036515.9473−632.644−2133.45−233.831−1363.8−2793.311804.646−1484.46−1129.18375.9521−995.2326,940.9427,342.9333,316.37 \>80−2210.66−1113.08−169.061−1806.11892.5153−297.992−451.89716.11853386.46421645.557−342.335140.223−925.094−1278.832066.425−156.349460.59−827.155−2429.7627,010.2427,247.627,388.0651,528.18BMI Overweight3529.466573.0519−339.4−552.401250.321924.09107739.0862109.069−443.283491.4164290.0057−150.674−73.1737−792.842−161.863724.8933−623.956−1356.181204.683−556.359−313.42538.44737−1558.259173.863 Obese3521.786400.006−595.534−726.146−612.32−32.3199604.383290.40263−260.271−246.0151816.794−373.677−373.834−3086.28−306.06117.209−1073.128.073191280.047−2138.66−816.066193.7971−609.1375204.19712,842.01 Morbidly obese−118.211−9986.43−9469.14−2409.75−2017.0940.761921044.331456.362986.13023133.2091577.67233.320344273.654−6030.72−2071.962339.319.31831−1655.311015.4994159.0433032.1266170.165360.115745.5266500.394388509.5Smoking Previous3051.792−192.533−525.105735.3619147.8917−410.739−357.737167.0641−65.6603−492.7341603.186−316.844−1847.56−829.91191.54407−1454.3−945.7441053.433−61.0395−905.897−1423.65−677.65−1246.05−968.874-696.796−4306.39446.943 Current3021.2911286.492−351.976619.13371659.942−449.125−294.024231.7881−115.202−93.4865785.4893216.0982−2526.05−1053.26−581.953−978.082−1439.441179.949787.86711593.9451184.4582831.6252421.957409.944639.0463−575.6625894.28114,982.78Constant−650.554−8561.44−9019.26−3331.26−50,134.5−48,152.1−49,973.645,313.9646,188.362439.9252001.973−4320.44−6659.011944.855−5262.25−9175.75−10,217.55459.5173663.643−26,755.5−26,623.3−26,969.7−26,842.4−4592.3−3397.78−9238.54−2227.81−6309.8493,066.23[^28]
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[^1]: Data presented as mean ± standard deviation or n (%).

[^2]: Abbreviations: ECG = electrocardiogram; NMIBC = non--muscle-invasive bladder cancer.

[^3]: The number of patients experiencing a recurrence exceeded the sum of graded recurrences because of missing grade data and patients experiencing multiple recurrences of different grades.

[^4]: Data presented as mean (95% confidence interval).

[^5]: Abbreviations: HRQoL = health-related quality of life; MIBC = muscle-invasive bladder cancer; NA = not applicable; NMIBC = non--muscle-invasive bladder cancer.

[^6]: Multivariate HRQoL longitudinal model controlled for baseline EQ-5D score, treatment (celecoxib), patient characteristics, bladder cancer history, annual time dummies, and events.

[^7]: *P* \< .01.

[^8]: Abbreviations: HRQoL = health-related quality of life; MIBC = muscle-invasive bladder cancer; NA = not applicable; NMIBC = non--muscle-invasive bladder cancer.

[^9]: Predicted values from a multivariate longitudinal panel cost-related analysis controlling for treatment, patient characteristics, risk group, annual time dummies, bladder cancer events, and interactions.

[^10]: Abbreviations: 5-FU = 5-fluorouracil; CC = complexity and comorbidity; EL = elective inpatient; EL XS = elective inpatient excess bed days; eMIT = electronic market information tool; GP = general practitioner; HRGs = healthcare resource groups; HRQoL = health-related quality of life; MIBC = muscle-invasive bladder cancer; MMC = mitomycin; NA = not applicable; NHS = National Health Service; NICE = National Institute for Health and Care Excellence; NMIBC = non--muscle-invasive bladder cancer; PSSRU = Personal Social Service Research Unit; TOA = total outpatient attendance.

[^11]: Inflated to 2017 prices using the PSSRU hospital and community health services index; presented costs were rounded up to the nearest pound sterling.

[^12]: Duration of 135 days used in accordance with reference material and per day NHS schedule reference for 2016-2017 costs applied.

[^13]: Specific chemotherapy unit costs were calculated as the product of the specific drug costs (using eMit), dosage, and observed/recommended number of cycles (recommended schedules from the NHS Cancer Network were used if trial information was missing).

[^14]: Abbreviations: BMI = body mass index; ECG = electrocardiography; EQ-5D = EuroQoL 5 dimension.

[^15]: Patient gender (female = 0; male = 1); ECG result (normal = 1; abnormal = 0); Celecoxib (placebo arm = 0; treatment arm = 1); history (no history of NMIBC = 0; history of NMIBC = 1); diabetes (no diabetes = 0; diabetes = 1).

[^16]: Abbreviations: BMI = body mass index; ECG = electrocardiography.

[^17]: Patient gender (female = 0; male = 1); ECG result (normal = 1; abnormal = 0); Celecoxib (placebo arm = 0; treatment arm = 1); history (no history of NMIBC = 0; history of NMIBC = 1); diabetes (no diabetes = 0; diabetes = 1).

[^18]: Abbreviations: EQ-5D = EuroQoL 5 dimension; HR = high-risk (patients); IR = intermediate-risk (patients); MIBC = muscle-invasive bladder cancer; NMIBC = non--muscle-invasive bladder cancer.

[^19]: For cases in which multiple NMIBC recurrences had developed between the EQ-5D and/or annual cost assessments, the analysis set was applied to the recurrence with the highest grade recorded (see the "Materials and Methods" section for details).

[^20]: Abbreviations: BOXIT = bladder COX-2 (cyclooxygenase-2) inhibition trial; EQ-5D = EuroQoL 5 dimension; SD = standard deviation.

[^21]: Abbreviations: BOXIT = bladder COX-2 (cyclooxygenase-2) inhibition trial; EQ-5D = EuroQoL 5 dimension; SD = standard deviation.

[^22]: Abbreviations: BMI = body mass index; CI = confidence interval; ECG = electrocardiography; EQ-5D = EuroQoL 5 dimension; HRQoL = health-related quality of life; SE = standard error; TCC = transitional cell carcinoma.

[^23]: Abbreviations: BMI = body mass index; CI = confidence interval; ECG = electrocardiography; EQ-5D = EuroQoL 5-dimension; HRQoL = health-related quality of life; SE = standard error; TCC = transitional cell carcinoma.

[^24]: Abbreviations: BMI = body mass index; CI = confidence interval; ECG = electrocardiography; EQ-5D = EuroQoL 5-dimension; HRQoL = health-related quality of life; SE = standard error; TCC = transitional cell carcinoma.

[^25]: Abbreviations: BMI = body mass index; CI = confidence interval; ECG = electrocardiography; EQ-5D = EuroQoL 5-dimension; HRQoL = health-related quality of life; SE = standard error; TCC = transitional cell carcinoma.

[^26]: Abbreviations: BMI = body mass index; CI = confidence interval; SE = standard error; TCC = transitional cell carcinoma.

[^27]: Abbreviations: BMI = body mass index; CI = confidence interval; ECG = electrocardiography; EQ-5D = EuroQoL 5 dimension; HRQoL = health-related quality of life; SE = standard error; TCC = transitional cell carcinoma.

[^28]: Abbreviations: BMI = body mass index; CI = confidence interval; ECG = electrocardiography; HR = high risk; HRQoL = health-related quality of life; SE = standard error; TCC = transitional cell carcinoma.
